Health Canada has approved a new drug treatment for adults living with Fabry disease, a rare genetic disorder that can affect multiple organs and impact the quality of life.

An FDA panel of experts has called for a loosening of regulations and expanding access to testosterone replacement therapy.

Elfabrio® (pegunigalsidase alfa for injection) is an enzyme replacement therapy indicated for the longterm treatment of adult ...